BioMarin Pharma Files 2024 Annual Report
Ticker: BMRN · Form: 10-K · Filed: Feb 24, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 10-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceutical
TL;DR
BioMarin dropped its 2024 10-K. All systems go for now.
AI Summary
BioMarin Pharmaceutical Inc. filed its 10-K for the fiscal year ending December 31, 2024, on February 24, 2025. The company, headquartered in Novato, CA, operates in the pharmaceutical preparations sector. Key financial details and operational highlights for 2024 are presented in this comprehensive annual report.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of BioMarin's financial performance, strategic initiatives, and risk factors for the past fiscal year, crucial for understanding the company's current standing and future outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, BioMarin faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.
Key Players & Entities
- BIOMARIN PHARMACEUTICAL INC (company) — Filer
- NOVATO, CA (location) — Headquarters
- 2024-12-31 (date) — Fiscal Year End
- 2025-02-24 (date) — Filing Date
- 4155066700 (phone_number) — Business Phone
FAQ
What was BioMarin's total revenue for the fiscal year 2024?
The provided text does not contain specific revenue figures for fiscal year 2024.
What are the primary business segments of BioMarin Pharmaceutical Inc.?
The filing mentions 'bmrn:segment' indicating distinct business segments, but specific segment names and their financial contributions are not detailed in this excerpt.
When was BioMarin Pharmaceutical Inc. incorporated?
The company was incorporated in Delaware (DE).
What is the SEC file number for BioMarin Pharmaceutical Inc.'s filings?
The SEC file number is 000-26727.
Does the filing mention any specific therapies or products developed by BioMarin?
The filing includes a reference to 'bmrn:therapy', suggesting the company focuses on therapeutic areas, but specific product names are not listed in this excerpt.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 24, 2025 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).